Sub-classification of intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas

Koichiro Yamakado, Shozo Hirota

Abstract

Hepatocellular carcinoma (HCC), the fifth most common cancer in the world, shows increasing incidence worldwide. Curative treatments such as hepatectomy, liver transplantation, and radiofrequency ablation are applied in only 30%-60% of cases. Most remaining patients receive transarterial chemoembolization (TACE). Patients with intermediate-stage HCCs are regarded as good candidates for TACE. However, the intermediate stage includes non-homogeneous patients. Some movements are underway to stratify patients using prognostic factors to identify patient groups exhibiting greater benefit from TACE than other patient groups. This review describes two substaging systems that subclassify intermediate-stage HCCs and discusses the importance of dividing intermediate-stage patients.

Key words: Hepatocellular carcinoma; Intermediate-stage; Chemoembolization; Child-Pugh score; Prognosis

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Correspondence to: Koichiro Yamakado, MD, Department of Radiology, Hyogo College of Medicine, 1-1 Mukogawa, Nishinomiya, Hyogo 663-8501, Japan.

Received: April 21, 2015
Peer-review started: April 22, 2015
First decision: June 2, 2015
Revised: June 17, 2015
Accepted: September 2, 2015
Article in press: September 2, 2015
Published online: October 7, 2015

INTRODUCTION

Hepatocellular carcinoma (HCC), the fifth most common cancer in the world, shows increasing incidence worldwide. Curative treatments such as hepatectomy, liver
transplantation, and radiofrequency ablation (RFA) are applicable in only 30%-60% of patients having HCCs[1]. Most remaining patients undergo transarterial chemoembolization (TACE) as a palliative treatment. Several studies have demonstrated that TACE provides better survival than the best supportive care[2-5].

The Barcelona Clinic Liver Cancer (BCLC) staging system, which has come to be accepted world-wide for clinical practice, divides HCC patients according to five stages (0, A, B, C, and D) depending on tumor-status-related parameters (size, number, vascular invasion, N1, M1), liver function (Child-Pugh grade), and health status (ECOG)[6]. In fact, TACE is recommended as the standard treatment, which is positioned as a palliative treatment, of BCLC stage-B HCC patients[2]. Actually, BCLC stage-B, which is defined as intermediate stage, includes diverse patients having Child-Pugh grade-A and grade-B liver function with four or more tumors irrespective of size, or 2-3 tumors larger than 3 cm in maximal diameter, in the absence of cancer-related symptoms, macrovascular invasion, or extrahepatic spread[2]. Untreated patients at an intermediate stage - BCLC stage-B reportedly present median survival of 16 mo[7,8], or 49% at two years[9]. TACE can extend the survival of these patients to a median of up to 19-20 mo according to RCT and meta-analysis of pooled data[3].

Although inhomogeneous patients make up the intermediate stage, it remains unclear whether there might be any subgroup stratification for which TACE can provide better prognosis than others. To explore this question, there are movements underway to divide the intermediate stage into several substages to stratify patients based on the prognosis following TACE.

This review presents subclassification of the intermediate stage and describes new strategies to treat intermediate-stage HCCs.

### BOLONDI SUBGROUP SYSTEM

Bolondi et al[9] advocated the division of the intermediate stage to tailor therapeutic interventions based on the evidence and expert opinion available to date. To distinguish major from minor tumor burdens, which would influence the allocation of patients to TACE/TAE or to alternative treatments such as radioembolization, transplantation or sorafenib, they selected the up-to-seven (up-to-7) criterion, which enables identification of a subgroup of patients with long survival after transplantation[10]. Regarding liver function, subgroups are defined by the Child-Pugh score and grade. They divided the intermediate stage into four sub-stages and suggest recommended treatments based on each sub-stage (Table 1).

Recently, one study validated this substaging system[11]. The system respectively classified 101 (21.7%), 232 (49.8%), 35 (7.5%), and 98 (21.0%) patients as B1, B2, B3, and B4. Median survival times were 41.0 mo, 22.1 mo, 14.1 mo, and 17.2 mo, respectively, in B1, B2, B3, and B4 patients. A significant difference was found in median survival time between B1 and B2 (P < 0.001), and B2 and B3 (P = 0.004), but not between B3 and B4 (P = 0.48).

In the Bolondi substaging system, TACE is recommended as the first therapeutic option for patients with well-preserved liver function (Child-Pugh scores 5-7) (B1 and B2) (Table 1). However, TACE is not recommended as the first therapeutic option in patients with Child-Pugh scores of 8 and 9 (B4). Furthermore, research trials are recommended for patients with Child-Pugh score 7 liver function and HCCs beyond up-to-7 criterion.

### PROPOSAL FROM THE JAPANESE SOCIETY OF TRANSCATHETER HEPATIC ARTERIAL EMBOLIZATION

The Japanese Society of Transcatheter Hepatic Arterial Embolization (JSTHAE) proposed an intermediate-stage subclassification using 4-of-7 cm (4-of-7 cm) criterion and the Child-Pugh score[12,13]. Yamakado et al[12] demonstrated that four tumors measuring 7 cm or smaller (4-of-7 cm criterion) and Child-Pugh grade-A were favorable prognostic factors for intermediate-stage HCC patients. First, they divided the intermediate stage into four subgroups by combination of 4-of-7 cm (in and out) and Child-Pugh grade (A and B). A patient subgroup including patients having a Child-Pugh grade-A liver profile and HCC lesions within the 4-of-7 cm criterion exhibited significantly better overall survival than the other three patient subgroups[12]. However, it was impossible to find a patient subgroup that does not reap a benefit from TACE. They sought poor prognostic factors by assessing the relation between the Child-Pugh score and prognosis after TACE[13]. Two-year survival rates were 77.5% in Child-Pugh-5 patients (P = 0.047, vs Child-Pugh-6), 65.1% in Child-Pugh-6 patients (P
Kadalayil et al\textsuperscript{[14]} have proposed the Hepatoma arterial-embolisation prognostic (HAP) score to predict clinical outcomes after TACE. They use the serum albumin level, bilirubin level, alpha-fetoprotein level, and tumor size of 7 cm as prognostic factors. Hucke et al\textsuperscript{[15]} have developed the Selection for TrAnsarterial chemoembolisation TrEatment (STATE) score in order to guide the decision for the first treatment with TACE in patients with HCCs. They used the serum albumin level, up-to-seven criteria, and C-reactive protein\textsuperscript{[16]}.

There have been no consensus which subclassification or scoring system is superior to others.

Recent studies have demonstrated the utility of hepatectomy and RFA even in intermediate-stage HCC patients\textsuperscript{[16,18]}. Results of many studies have demonstrated that tumor diameter is not a limitation of hepatectomy with 5-year survival rates of 20%-30% in patients with large HCCs greater than 10 cm that are much better than those derived from patient history\textsuperscript{[19,20]}. Although therapeutic results following hepatectomy worsen as the tumor number increases, these results are better than those following other palliative treatments and supportive care\textsuperscript{[21,22]}. No evidence exists for a tumor number that provides a survival benefit to patients undergoing surgical intervention, although a tumor number of up to three has been widely accepted as a good indication for locoregional treatments such as RFA. Therefore, hepatectomy is recommended when the tumor number is 3 or fewer, irrespective of tumor size.

Bolondi et al\textsuperscript{[11]} recommended a combination of RFA with TACE as the alternative to TACE in B1 subgroup patients (Table 1). Yamakado et al\textsuperscript{[13]} reported the application of curative treatments such as hepatectomy and RFA in the intermediate stage. However, it is not clear for two criteria derived from the tumor number and size: Results show that the up-to-seven criterion and the 4-of-7 cm criterion can be useful milestones for locoregional treatment in patients with intermediate-stage HCCs.

Bolondi et al\textsuperscript{[11]} suggested the use of sorafenib in B2 and B3 substage patients (Table 1). After TACE fails to control HCC lesions, sorafenib is recommended to treat HCCs\textsuperscript{[23]}. The median survival times after sorafenib administration were 10.7 mo in SHARP trial and 6.5 mo in the Asia-Pacific trial, although not all patients had TACE-refractory HCC in these studies\textsuperscript{[23,24]}. According to Japanese guidelines, sorafenib is usually used after both TACE and hepatic arterial infusion chemotherapy fail to control disease, although few data exist to show that hepatic arterial infusion chemotherapy is useful for prolonging survival of TACE-refractory patients\textsuperscript{[25,26]}. One prospective study featuring hepatic arterial infusion chemotherapy using a suspension of iodized-oil and cisplatinum has shown the encouraging one-year survival rate of 57% with median survival time of 13 mo in patients with TACE-refractory HCCs\textsuperscript{[27]}. However, another study featuring fine-powder formulation of cisplatin has shown limited clinical utility, with a one-

### DISCUSSION

The problem of the BCLC staging system lies in its simplicity of recommending only TACE, although the intermediate-stage includes an extremely diverse set of patients. This review introduced two substaging systems to divide intermediate stage patients. The review shows that patient subgroups that benefit more from TACE than other subgroups can be identified. Subgroups including patients having a better liver profile (Child-Pugh grade-A) and less tumor burden (up-to-7 or 4-of-7 cm criterion) benefit more. Furthermore, both substaging systems reveal patient subgroups that do not reap a benefit from TACE. Bolondi et al\textsuperscript{[11]} do not recommend TACE in Child-Pugh score of 7 patients beyond up-to-7 criterion (B3) and Child-Pugh score of 8-9 patients, irrespective of the HCC condition (B4).

However, Yamakado et al\textsuperscript{[13]} pointed out that TACE is not as beneficial as patient history for patients with Child-Pugh score 9. Little controversy has arisen for alternatives to TACE for patients with poor liver function.

Two prognostic scoring systems have been recently developed in patients with HCC who undergo HCCs\textsuperscript{[11,14,15]}.
year survival rate of 27% and median survival time of 7.1 months in patients with TACE failure or HCCs.[15]

In conclusion, movements to divide the intermediate stage of HCCs are underway because of the diversity of intermediate-stage patients. Validation of the staging system must be done to allocate therapy appropriately in the new classifying systems, not only with TACE but also with loco-regional treatments such as hepatectomy and RFA, liver transplantation, hepatic arterial infusion chemotherapy, sorafenib, and Best supportive care depending on the tumor number and size, and liver function reserve.

REFERENCES

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet* 2003; 362: 1907-17. [PMID: 14667750 DOI: 10.1016/S0140-6736(03)14664-1]
2. Cammà C, Schepis F, Orlando A, Albaneese M, Shahied L, Tresiviani F, Andreone P, Ciraci A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. *Radiology* 2002; 224: 47-54. [PMID: 12091661 DOI: 10.1148/radiol.2241011262]
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. *Hepatology* 2003; 37: 429-442. [PMID: 12546794 DOI: 10.1015/j.hepb.2003.5047]
4. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* 2002; 359: 1734-1739. [PMID: 12049862 DOI: 10.1016/S0140-6736(02)08064-X]
5. Lo CM, Ngan H, Tso WK, Lam CM, Poon RT, Fan ST, Ngan H, Shim JH, Kim SO, Kim KM, Lim YS, Lee HC. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. *J Gastroenterol Hepatol* 2014; 29: 787-793. [PMID: 24224567 DOI: 10.1111/jgh.12452]
6. Llovet JM, Galera J, Pina G, Casas J, Carratalá E. Subclassifying the intermediate stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. *Jpn J Radiol* 2013; 31: 260-265. [PMID: 24516156 DOI: 10.1007/s11604-014-0298-9]
7. Yamakado K, Miyayama S, Hirota S, Mizumura K, Nakamura K, Inaba Y, Maeda H, Matsuo K, Nishida N, Aramaki T, Anai H, Koura S, Okawa S, Watanabe K, Yasumoto T, Furuchi K, Yamaguchi M. Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade: sub-classifying the intermediate stage (BCLC Liver Cancer stage C). *Jpn J Radiol* 2014; 32: 644-649. [PMID: 25213426 DOI: 10.1007/s11604-014-0358-8]
8. Kadalayil L, Benini R, Pallan L, O’Beirne J, Marelli L, Yu D, Hackshaw A, Fox R, Johnson P, Burroughs AK, Palmer DH, Meyer T. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. *Ann Oncol* 2013; 24: 2565-2570. [PMID: 23857958 DOI: 10.1093/annonc/mdt247]
9. Hackett A, Pinder M, Grazialedi I, Bota S, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M, Sieghart W. How to divide and classify intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage C). *Jpn J Radiol* 2014; 32: 1287-1296. [PMID: 25016222 DOI: 10.1111/j.1743-1662.2014.07002]
10. Ha Y, Shin JH, Kim SO, Kim KM, Lim YS, Lee HC. Hepatocellular carcinoma. *WJG* 2009; 15: 3502-3512. [PMID: 19508734 DOI: 10.3748/wjg.v15.i19.3502]
11. Yamakado K, Miyayama S, Hirota S, Mizumura K, Nakamura K, Inaba Y, Yamamoto S, Matsuo K, Nishida N, Aramaki T, Anai H, Kura S, Okawa S, Watanabe K, Yasumoto T, Furuchi K, Yamaguchi M. Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage C). *Jpn J Radiol* 2014; 32: 644-649. [PMID: 25213426 DOI: 10.1007/s11604-014-0358-8]
12. Yamakado K, Miyayama S, Hirota S, Mizumura K, Nakamura K, Inaba Y, Yamamoto S, Matsuo K, Nishida N, Aramaki T, Anai H, Kura S, Okawa S, Watanabe K, Yasumoto T, Furuchi K, Yamaguchi M. Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage C). *Jpn J Radiol* 2014; 32: 644-649. [PMID: 25213426 DOI: 10.1007/s11604-014-0358-8]
13. Yamakado K, Miyayama S, Hirota S, Mizumura K, Nakamura K, Inaba Y, Yamamoto S, Matsuo K, Nishida N, Aramaki T, Anai H, Kura S, Okawa S, Watanabe K, Yasumoto T, Furuchi K, Yamaguchi M. Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage C). *Jpn J Radiol* 2014; 32: 644-649. [PMID: 25213426 DOI: 10.1007/s11604-014-0358-8]
14. Kadalayil L, Benini R, Pallan L, O’Beirne J, Marelli L, Yu D, Hackshaw A, Fox R, Johnson P, Burroughs AK, Palmer DH, Meyer T. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. *Ann Oncol* 2013; 24: 2565-2570. [PMID: 23857958 DOI: 10.1093/annonc/mdt247]
15. Hackett A, Pinder M, Grazialedi I, Bota S, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M, Sieghart W. How to divide and classify intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage C). *Jpn J Radiol* 2014; 32: 1287-1296. [PMID: 25016222 DOI: 10.1111/j.1743-1662.2014.07002]
16. Ha Y, Shin JH, Kim SO, Kim KM, Lim YS, Lee HC. Hepatocellular carcinoma. *WJG* 2009; 15: 3502-3512. [PMID: 19508734 DOI: 10.3748/wjg.v15.i19.3502]
Yamakado K et al. Sub-classification of intermediate-stage HCC

24 Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Votiots D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34 [PMID: 19095497 DOI: 10.1016/S1470-2045(08)70285-7]

25 Japan Society of Hepatology: Clinical practice guidelines for hepatocellular carcinoma (2013 version). Tokyo, Japan: Kanehara, 2013

26 Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M; HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-364 [PMID: 21829027 DOI: 10.1159/000327577]

27 Takaki H, Yamakado K, Tsurusaki M, Yasumoto T, Baba Y, Narimatsu Y, Shimohira M, Yamaguchi M, Matsuura K, Inaba Y, Mikami K, Watanabe R, Nishida N, Anai H, Kakizawa H, Hirota S. Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage (Barcelona Clinic Liver Cancer stage-B or stage-C) hepatocellular carcinoma: multicenter phase-II clinical study. Int J Clin Oncol 2015; 20: 745-754 [PMID: 25432660 DOI: 10.1007/s10147-014-0773-4]

28 Iwasa S, Ikeda M, Okusaka T, Ueno H, Morizane C, Nakachi K, Mitsunaga S, Kondo S, Hagihara A, Shimizu S, Satake M, Arai Y. Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Jpn J Clin Oncol 2011; 41: 770-775 [PMID: 21459893 DOI: 10.1093/jjco/hyr037]

P- Reviewer: Augustin G, Corrales FJ, Kim YJ  S- Editor: Ma YJ  L- Editor: A  E- Editor: Wang CH
